Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals

被引：3

作者：

Denker, Sophy ^{[1
,2
,3
,4
]}

Bittner, Aitomi ^{[1
,2
,3
,4
]}

Frick, Mareike ^{[1
,2
,3
]}

Kase, Julia ^{[1
,2
,3
]}

Hoffmann, Joerg ^{[5
]}

Trenker, Corinna ^{[5
]}

Keller, Ulrich ^{[1
,2
,3
,6
,7
,8
]}

Bogner, Christian ^{[9
]}

Huettmann, Andreas ^{[10
]}

Duerig, Jan ^{[10
]}

Janz, Martin ^{[1
,2
,3
,8
]}

Mathas, Stephan ^{[1
,2
,3
,8
]}

Marks, Reinhard ^{[11
,12
]}

Krohn, Ulrike ^{[11
,12
]}

Na, Il-Kang ^{[1
,2
,3
,4
,6
,7
,13
]}

Bullinger, Lars ^{[1
,2
,3
]}

Schmitt, Clemens A. ^{[1
,2
,3
,14
]}

机构：

[1] Charite Univ Med Berlin, Berlin, Germany

[2] Free Univ Berlin, Med Dept, Div Hematol Oncol & Tumor Immunol, Charitepl 1, D-10117 Berlin, Germany

[3] Humboldt Univ, Charitepl 1, D-10117 Berlin, Germany

[4] Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany

[5] Philipps Univ Marburg, Univ Hosp Giessen & Marburg, Dept Hematol Oncol Immunol, Marburg, Germany

[6] German Canc Res Ctr, Heidelberg, Germany

[7] German Canc Consortium DKTK, Heidelberg, Germany

[8] Helmholtz Assoc, Max Delbruck Ctr Mol Med, Berlin, Germany

[9] Tech Univ Munich, Med Clin & Policlin 2, Klinikum Rechts Isar, Munich, Germany

[10] Univ Duisburg Essen, Klin Hamatol, Univ Klinikum Essen, Essen, Germany

[11] Univ Freiburg, Fac Med, Dept Hematol Oncol Stem Cell Transplantat, Freiburg, Germany

[12] Univ Freiburg, Med Ctr, Dept Hematol Oncol Stem Cell Transplantat, Freiburg, Germany

[13] Max Delbruck Ctr Mol Med, Expt & Clin Res Ctr ECRC, Berlin, Germany

[14] Johannes Kepler Univ Linz, Kepler Univ Hosp, Dept Hematol & Oncol, Linz, Austria

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 01期

关键词：

Lymphoma and Hodgkin disease; biomarker; novel study design; targeted therapy; prediction; diffuse large B-cell lymphoma; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; RANDOMIZED CONTROLLED-TRIAL; MOLECULAR CHARACTERISTICS; CHEMOTHERAPY; MULTICENTER; VINCRISTINE; DOXORUBICIN; THERAPY; AGE;

D O I：

10.1080/10428194.2021.1964024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Diffuse large-cell B-cell lymphoma (DLBCL) is the most common lymphoid malignancy. About 30-40% of the patients will not be cured by standard Rituximab (R)-CHOP-like immune-chemotherapy, and many of them experience relapse and eventually succumb to their disease. Enhancing first-line efficacy in patients at higher risk, among them many elderly, is key to improve long-term outcomes. Numerous attempts to combine R-CHOP with targeted agents failed in large randomized phase III trials. The addition of Ibrutinib enhanced survival in younger patients, but increased toxicity across all age groups, especially in the elderly. Older DLBCL patients impose particular challenges, since they often present with more advanced disease, and exhibit treatment-relevant comorbidities. ImbruVeRCHOP trial aims at identifying patients who need that benefit from rationally augmented first-line regimens without experiencing overt toxicity and detecting their molecular signatures of response. This first analysis presents encouraging feasibility, safety, and preliminary response data in elderly high-risk DLBCL patients.

引用

页码：84 / 92

页数：9

共 32 条

[11] Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte [J].

Feugier, P ;

Van Hoof, A ;

Sebban, C ;

Solal-Celigny, P ;

Bouabdallah, R ;

Fermé, C ;

Christian, B ;

Lepage, E ;

Tilly, H ;

Morschhauser, F ;

Gaulard, P ;

Salles, G ;

Bosly, A ;

Gisselbrecht, C ;

Reyes, F ;

Coiffier, B .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4117-4126

[12] Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma [J].

Hirakawa, Tsuneaki ;

Yamaguchi, Hiroki ;

Yokose, Norio ;

Gomi, Seiji ;

Inokuchi, Koiti ;

Dan, Kazuo .

ANNALS OF HEMATOLOGY, 2010, 89 (09) :897-904

[13] Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial [J].

Johnson, Peter ;

Balasubramanian, Sriram ;

Hodkinson, Brendan ;

Schaffer, Michael ;

Parisi, Lori ;

Shreeve, S. Martin ;

Sun, Steven ;

Vermeulen, Jessica ;

Sehn, Laurie H. ;

Staudt, Louis ;

Younes, Anas ;

Wilson, Wyndham .

BLOOD, 2019, 134

[14] Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma [J].

Klapper, Wolfram ;

Kreuz, Markus ;

Kohler, Christian W. ;

Burkhardt, Birgit ;

Szczepanowski, Monika ;

Salaverria, Itziar ;

Hummel, Michael ;

Loeffler, Markus ;

Pellissery, Shoji ;

Woessmann, Wilhelm ;

Schwaenen, Carsten ;

Truemper, Lorenz ;

Wessendorf, Swen ;

Spang, Rainer ;

Hasenclever, Dirk ;

Siebert, Reiner .

BLOOD, 2012, 119 (08) :1882-1887

[15] Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial [J].

Kuhnl, A. ;

Cunningham, D. ;

Counsell, N. ;

Hawkes, E. A. ;

Qian, W. ;

Smith, P. ;

Chadwick, N. ;

Lawrie, A. ;

Mouncey, P. ;

Jack, A. ;

Pocock, C. ;

Ardeshna, K. M. ;

Radford, J. ;

McMillan, A. ;

Davies, J. ;

Turner, D. ;

Kruger, A. ;

Johnson, P. W. ;

Gambell, J. ;

Rosenwald, A. ;

Ott, G. ;

Horn, H. ;

Ziepert, M. ;

Pfreundschuh, M. ;

Linch, D. .

ANNALS OF ONCOLOGY, 2017, 28 (07) :1540-1546

[16] Stromal Gene Signatures in Large-B-Cell Lymphomas [J].

Lenz, G. ;

Wright, G. ;

Dave, S. S. ;

Xiao, W. ;

Powell, J. ;

Zhao, H. ;

Xu, W. ;

Tan, B. ;

Goldschmidt, N. ;

Iqbal, J. ;

Vose, J. ;

Bast, M. ;

Fu, K. ;

Weisenburger, D. D. ;

Greiner, T. C. ;

Armitage, J. O. ;

Kyle, A. ;

May, L. ;

Gascoyne, R. D. ;

Connors, J. M. ;

Troen, G. ;

Holte, H. ;

Kvaloy, S. ;

Dierickx, D. ;

Verhoef, G. ;

Delabie, J. ;

Smeland, E. B. ;

Jares, P. ;

Martinez, A. ;

Lopez-Guillermo, A. ;

Montserrat, E. ;

Campo, E. ;

Braziel, R. M. ;

Miller, T. P. ;

Rimsza, L. M. ;

Cook, J. R. ;

Pohlman, B. ;

Sweetenham, J. ;

Tubbs, R. R. ;

Fisher, R. I. ;

Hartmann, E. ;

Rosenwald, A. ;

Ott, G. ;

Muller-Hermelink, H. -K ;

Wrench, D. ;

Lister, T. A. ;

Jaffe, E. S. ;

Wilson, W. H. ;

Chan, W. C. ;

Staudt, L. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (22) :2313-2323

[17] Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma [J].

Long, G. V. ;

Stroyakovskiy, D. ;

Gogas, H. ;

Levchenko, E. ;

de Braud, F. ;

Larkin, J. ;

Garbe, C. ;

Jouary, T. ;

Hauschild, A. ;

Grob, J. J. ;

Sileni, V. Chiarion ;

Lebbe, C. ;

Mandala, M. ;

Millward, M. ;

Arance, A. ;

Bondarenko, I. ;

Haanen, J. B. A. G. ;

Hansson, J. ;

Utikal, J. ;

Ferraresi, V. ;

Kovalenko, N. ;

Mohr, P. ;

Probachai, V. ;

Schadendorf, D. ;

Nathan, P. ;

Robert, C. ;

Ribas, A. ;

DeMarini, D. J. ;

Irani, J. G. ;

Casey, M. ;

Ouellet, D. ;

Martin, A. -M. ;

Le, N. ;

Patel, K. ;

Flaherty, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (20) :1877-1888

[18] ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma [J].

Nowakowski, Grzegorz S. ;

Chiappella, Annalisa ;

Witzig, Thomas E. ;

Spina, Michele ;

Gascoyne, Randy D. ;

Zhang, Lei ;

Flament, Jocelyne ;

Repici, Jacqueline ;

Vitolo, Umberto .

FUTURE ONCOLOGY, 2016, 12 (13) :1553-1563

[19] Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC [J].

Paul, Ulrike ;

Richter, Julia ;

Stuhlmann-Laiesz, Christiane ;

Kreuz, Markus ;

Nagel, Inga ;

Horn, Heike ;

Staiger, Annette M. ;

Aukema, Sietse M. ;

Hummel, Michael ;

Ott, German ;

Spang, Rainer ;

Rosenwald, Andreas ;

Feller, Alfred C. ;

Cogliatti, Sergio ;

Stein, Harald ;

Hansmann, Martin-Leo ;

Moller, Peter ;

Szczepanowski, Monika ;

Burkhardt, Birgit ;

Pfreundschuh, Michael ;

Schmitz, Norbert ;

Loeffler, Markus ;

Truemper, Lorenz ;

Siebert, Reiner ;

Klapper, Wolfram .

LEUKEMIA & LYMPHOMA, 2018, 59 (05) :1213-1221

[20] Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60) [J].

Pfreundschuh, Michael ;

Schubert, Joerg ;

Ziepert, Marita ;

Schmits, Rudolf ;

Mohren, Martin ;

Lengfelder, Eva ;

Reiser, Marcel ;

Nickenig, Christina ;

Clemens, Michael ;

Peter, Norma ;

Bokemeyer, Carsten ;

Eimermacher, Hartmut ;

Ho, Anthony ;

Hoffmann, Martin ;

Mertelsmann, Roland ;

Truemper, Lorenz ;

Balleisen, Leopold ;

Liersch, Ruediger ;

Metzner, Bernd ;

Hartmann, Frank ;

Glass, Bertram ;

Poeschel, Viola ;

Schmitz, Norbert ;

Ruebe, Christian ;

Feller, Alfred C. ;

Loeffler, Markus .

LANCET ONCOLOGY, 2008, 9 (02) :105-116

← 1 2 3 4 →